Arrowhead Pharma (ARWR) Reiterated at Overweight by Cantor Fitzgerald on ARO-MAPT Ph1 Data

October 15, 2026 7:57 AM

Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on Arrowhead Pharma (NASDAQ: ARWR).The analyst commented, "ARWR reported positive ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found